On 6 february, this newspaper (journalist chang jing zhao), a correspondent of the university of zhengzhou, was informed by journalists that zhang yi's team in the bioimmunotherapy district of the institution had been successful in treating a case of terminal ovarian cancer, which was re-emerging, using the internationally front-line car-t cell therapy technology. This treatment fills a gap in this field in henan province, where, according to a literature search, the patient has benefited the most from an international clinical study of car-t cells that use the target to mesothelin (a surface antigen, usually expressed in the inter-body cortex of the pleural, perimenary and heartbags) to treat repeated and difficult ovarian cancer。
Before receiving car-t-cell treatment, the patient, ms. Zhao, suffered from advanced ovarian cancer, experienced multiple operations, chemotherapy and target treatment, and the tumour was never controlled, and symptoms such as the reduction of white cells, the reduction of the platelets, the loss of liver and kidney function, the recurrence of nausea, vomiting, and the extremely poor quality of life and suffering. In august 2022, after receiving car-t-cell treatment, no other anti-oncological therapy was carried out. A monthly review revealed that many of the tumour stoves in the body were controlled and that there had been a marked improvement in the general state of appetite, physical strength, etc., and that there had been a good recovery of the haemorrhagic and biochemical indicators such as blood protocol, liver and kidney function and a marked improvement in the quality of life. At present, the patient has advanced beyond three months without illness。
According to zheng's bioimmunotherapy staff, the car-t is the embedded antigen receptor t-cell immunotherapy, which is based on the use of the patient's own immune cells, which, after in vitro modification, form a large number of car-t cells capable of targeting and eliminating cancer cells, which are then transferred back to the patient for the purpose of removing cancer cells. Car-t used to treat malignant tumours in the blood system in the past, and this new car-t treatment treats patients with late ovarian cancer as a real tumour, which is difficult to cure. The success of the mesothelincar-t-cell treatment was the result of the use of the target, giving new hope to patients with advanced ovarian cancer。
